Novel NMR Probe Technologies, GHz-class NMR
and Dynamics Software Enable New Research, and Advance Functional
Structural Biology and Drug Discovery
At the ICMRBS 2022 Conference, Bruker today announces a new 8
mm 15N TROSY Cryoprobe for enabling novel NMR functional
structural biology investigations into larger globular proteins and
protein complexes. The new technology also facilitates cell biology
research into highly dynamic intrinsically disordered proteins
(IDPs) or protein regions that often play key roles in signaling
pathways via phosphorylation, e.g. in cancer. The new 8 mm 15N
TROSY Cryoprobe provides twice the sensitivity of previous 5 mm
detection, and 50% greater 13C sensitivity at 800 MHz. It allows
researchers to obtain essential information in crowded IDP spectral
regions for the unambiguous assignment of IDP backbone
resonances.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220822005139/en/
Compact 1.0 GHz NMR magnet Ascend Evo for
structural biology applications and clinical research in
single-story laboratories (Graphic: Business Wire)
Dr. Haribabu (‘Hari’) Arthanari, Associate Professor in the
Department of Biological Chemistry and Molecular Pharmacology at
Harvard Medical School, and in the Department of Cancer Biology at
the Dana-Farber Cancer Institute, stated: “We can now greatly
expand the scientific scope of functional structural biology by
high-field NMR with 15N-detected experiments to study
non-deuterated protein systems, like disordered proteins or
globular proteins, which can now be made in flexible eukaryotic
expression systems. The new 8mm 15N TXO Cryoprobe holds promise to
unleash the power of 15N-detection at high fields. I am very
excited to see which previously inaccessible but important
scientific and pathobiology questions this innovative NMR
technology can address.”
Bruker also announces the technology introduction of a novel
160 kHz Ultra-fast spinning Magic Angle Spinning (MAS) NMR
probe for advancements in solid-state membrane protein, prion, and
aggregates research. This new probe, which mechanically spins
160,000 times per second, provides a further significant resolution
increase, and can record solids HCN NMR spectra in just tens of
minutes. The significantly increased new capabilities of this 160
kHz 0.4mm MAS probe at high NMR fields may enable novel insights
and discoveries in neurodegenerative diseases, like Parkinson’s and
Alzheimer’s, and in other cell and disease biology fields.
Dr. Guido Pintacuda, CNRS Research Director and Director of the
Lyon High-field NMR Center explained: “The new Bruker 160 kHz MAS
HCN probe will push structural, cellular and disease biology
research into the next phase of the solid-state NMR scientific
evolution. Not only will this expand the diversity and molecular
size range of biological systems such as membrane proteins, amyloid
fibrils, prions, and aggregates amenable for analysis by
solid-state NMR, but it will accelerate their investigation and
increase the amount of information that can be extracted from these
important biological systems.”
Bruker is also very pleased to announce the installation and
acceptance of the 1.2 GHz Avance™ NMR at University of Lille
in France, which will be a part of the national infrastructure
INFRANALYTICS. This first 1.2 GHz NMR in France will allow
researchers in Lille, and from all over France, to advance their
understanding of functional structural biology and advanced
materials.
Professor Jean-Pierre Simorre, Research Director, and Deputy
Director INC at CNRS, commented: “We are thrilled to have received
our 1.2 GHz NMR system. The power and resolution of 1.2 GHz will
provide the unique ability to study proteins in their natural state
and examine their structural details, including binding and
dynamics of molecular structures and complexes, for our fundamental
cell biology and pathobiology research.”
Professor Olivier Lafon at the University of Lille, and Director
of Lille High-Field NMR Facility, expanded: “The 1.2 GHz NMR
spectrometer will strongly improve the sensitivity and resolution
for quadrupolar isotopes, such as 14N, 17O, 25Mg, 33S, 63Cu, and
67Zn, in materials and solid-state biomolecules. This will notably
open new avenues for the study of dynamics, hydrogen bonds,
disulfide bonds and metal centers of many metalloproteins, nucleic
acids and carbohydrates."
Moreover, as announced at Euromar 2022, Bruker has received
three orders for compact 1.0 GHz NMR systems from the RIKEN Center
for Biosystems Dynamics Research in Yokohama, Japan, the Precision
Medicine and Metabolism Lab at CIC bioGUNE, and the BioNMR Group at
Universitat de Barcelona, both in Spain. The Ascend Evo 1.0
GHz NMR magnet utilizes hybrid high temperature superconductor
(HTS) technology for operation at 4.2 Kelvin in single-story labs.
The significantly reduced footprint, weight, and ceiling height,
along with a 65% reduction in helium consumption, provides more
structural biology principal investigators, universities, and
research centers, as well as biopharma companies access to the
sensitivity and resolution of GHz NMR. The 1.0 GHz system
complements Bruker’s well-established Avance Neo 1.1 GHz and 1.2
GHz two-story 2 Kelvin NMR systems.
Bruker now offers combined bioTop and
DynamicsCenter software to simplify and automate
experimental setup, measurements, and processing for protein
dynamics analysis. DynamicsCenter combines NMR assignments with 3D
protein structures imported from crystallography or cryo-EM.
Please join Bruker at ICMRBS at our booth for interaction with
our NMR and EPR teams.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220822005139/en/
Investor: Justin Ward Sr. Director, Investor Relations
& Corporate Development Bruker Corporation T: +1 (978) 663-3660
x1479 E: Investor.Relations@bruker.com Media: Thorsten
Thiel, Ph.D. VP of Group Marketing Bruker BioSpin T: +49 7243 769
5500 E: pr@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024